Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 2/2015

01-04-2015

Arctigenin Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rats

Authors: Xianbao Shi, Hongzhi Sun, Dun Zhou, Huanjiu Xi, Lina Shan

Published in: Inflammation | Issue 2/2015

Login to get access

Abstract

Arctigenin (ATG) has been reported to possess anti-inflammatory properties. However, the effects of ATG on lipopolysaccharide (LPS)-induced acute lung injury (ALI) remains not well understood. In the present study, our investigation was designed to reveal the effect of ATG on LPS-induced ALI in rats. We found that ATG pretreatment attenuated the LPS-induced ALI, as evidenced by the reduced histological scores, myeloperoxidase activity, and wet-to-dry weight ratio in the lung tissues. This was accompanied by the decreased levels of tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-1 (IL-6) in the bronchoalveolar lavage fluid. Furthermore, ATG downregulated the expression of nuclear factor kappa B (NF-κB) p65, promoted the phosphorylation of inhibitor of nuclear factor-κB-α (IκBα) and activated the adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPKα) in the lung tissues. Our results suggested that ATG attenuates the LPS-induced ALI via activation of AMPK and suppression of NF-κB signaling pathway.
Literature
1.
Costa, E.L., and M.B. Amato. 2013. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Current Opinion in Critical Care 19(1): 16–23.PubMedCrossRef
2.
van der Aman, J., M. Heijden, A. van Lingen, A.R. Girbes, G.P. van Nieuw Amerongen, V.W. van Hinsbergh, and A.B. Groeneveld. 2011. Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Critical Care Medicine 39(1): 89–97.PubMedCrossRef
3.
Mutz, C., V. Mirakaj, D.A. Vagts, P. Westermann, K. Waibler, K. Konig, T. Iber, G. Noldge-Schomburg, and P. Rosenberger. 2010. The neuronal guidance protein netrin-1 reduces alveolar inflammation in a porcine model of acute lung injury. Critical care (London, England) 14(5): R189.CrossRef
4.
Ni, Y.F., J.K. Kuai, Z.F. Lu, G.D. Yang, H.Y. Fu, J. Wang, F. Tian, X.L. Yan, Y.C. Zhao, Y.J. Wang, and T. Jiang. 2011. Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression. The Journal of Surgical Research 165(1): e29–35.PubMedCrossRef
5.
Ni, Y.F., J. Wang, X.L. Yan, F. Tian, J.B. Zhao, Y.J. Wang, and T. Jiang. 2010. Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice. Respiratory Research 11: 33.PubMedCentralPubMedCrossRef
6.
Luh, S.P., and C.H. Chiang. 2007. Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): the mechanism, present strategies and future perspectives of therapies. Journal of Zhejiang University. Science. B 8(1): 60–69.PubMedCentralPubMedCrossRef
7.
Bosma, K., V. Fanelli, and V.M. Ranieri. 2005. Acute respiratory distress syndrome: update on the latest developments in basic and clinical research. Current Opinion in Anaesthesiology 18(2): 137–145.PubMedCrossRef
8.
Lee, W.L., and G.P. Downey. 2001. Neutrophil activation and acute lung injury. Current Opinion in Critical Care 7(1): 1–7.PubMedCrossRef
9.
Chen, Z., X. Zhang, X. Chu, X. Zhang, K. Song, Y. Jiang, L. Yu, and X. Deng. 2010. Preventive effects of valnemulin on lipopolysaccharide-induced acute lung injury in mice. Inflammation 33(5): 306–314.PubMedCrossRef
10.
Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18(49): 6853–6866.PubMedCrossRef
11.
Yang, R., L. Yang, X. Shen, W. Cheng, B. Zhao, K.H. Ali, Z. Qian, and H. Ji. 2012. Suppression of NF-kappaB pathway by crocetin contributes to attenuation of lipopolysaccharide-induced acute lung injury in mice. European Journal of Pharmacology 674(2–3): 391–396.PubMedCrossRef
12.
Di, R., M.T. Huang, and C.T. Ho. 2011. Anti-inflammatory activities of mogrosides from Momordica grosvenori in murine macrophages and a murine ear edema model. Journal of Agricultural and Food Chemistry 59(13): 7474–81.PubMedCrossRef
13.
Bai, A., A.G. Ma, M. Yong, C.R. Weiss, Y. Ma, Q. Guan, C.N. Bernstein, and Z. Peng. 2010. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochemical Pharmacology 80(11): 1708–1717.PubMedCrossRef
14.
Nath, N., S. Giri, R. Prasad, M.L. Salem, A.K. Singh, and I. Singh. 2005. 5-Aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950) 175(1): 566–574.CrossRef
15.
Myerburg, M.M., J.D. King Jr., N.M. Oyster, A.C. Fitch, A. Magill, C.J. Baty, S.C. Watkins, J.K. Kolls, J.M. Pilewski, and K.R. Hallows. 2010. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. American Journal of Respiratory Cell and Molecular Biology 42(6): 676–684.PubMedCentralPubMedCrossRef
16.
Zhao, X., J.W. Zmijewski, E. Lorne, G. Liu, Y.J. Park, Y. Tsuruta, and E. Abraham. 2008. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 295(3): L497–504.PubMedCentralPubMedCrossRef
17.
Giri, S., N. Nath, B. Smith, B. Viollet, A.K. Singh, and I. Singh. 2004. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 24(2): 479–87.CrossRef
18.
Cho, M.K., Y.P. Jang, Y.C. Kim, and S.G. Kim. 2004. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition. International Immunopharmacology 4(10–11): 1419–1429.PubMedCrossRef
19.
Zhao, F., L. Wang, and K. Liu. 2009. In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. Journal of Ethnopharmacology 122(3): 457–462.PubMedCrossRef
20.
Chan, Y.S., L.N. Cheng, J.H. Wu, E. Chan, Y.W. Kwan, S.M. Lee, G.P. Leung, P.H. Yu, and S.W. Chan. 2011. A review of the pharmacological effects of Arctium lappa (burdock). Inflammopharmacology 19(5): 245–254.PubMedCrossRef
21.
Bastos, J.K., J.C. Carvalho, G.H. de Souza, A.H. Pedrazzi, and S.J. Sarti. 2001. Anti-inflammatory activity of cubebin, a lignan from the leaves of Zanthoxyllum naranjillo Griseb. Journal of Ethnopharmacology 75(2–3): 279–282.PubMedCrossRef
22.
Jang, Y.P., S.R. Kim, Y.H. Choi, J. Kim, S.G. Kim, G.J. Markelonis, T.H. Oh, and Y.C. Kim. 2002. Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. Journal of Neuroscience Research 68(2): 233–240.PubMedCrossRef
23.
Jang, Y.P., S.R. Kim, and Y.C. Kim. 2001. Neuroprotective dibenzylbutyrolactone lignans of Torreya nucifera. Planta Medica 67(5): 470–472.PubMedCrossRef
24.
Takasaki, M., T. Konoshima, K. Komatsu, H. Tokuda, and H. Nishino. 2000. Anti-tumor-promoting activity of lignans from the aerial part of Saussurea medusa. Cancer Letters 158(1): 53–59.PubMedCrossRef
25.
Cho, M.K., J.W. Park, Y.P. Jang, Y.C. Kim, and S.G. Kim. 2002. Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. International Immunopharmacology 2(1): 105–116.PubMedCrossRef
26.
Lee, J.Y., B.J. Cho, T.W. Park, B.E. Park, S.J. Kim, S.S. Sim, and C.J. Kim. 2010. Dibenzylbutyrolactone lignans from Forsythia koreana fruits attenuate lipopolysaccharide-induced inducible nitric oxide synthetase and cyclooxygenase-2 expressions through activation of nuclear factor-kappab and mitogen-activated protein kinase in RAW264.7 cells. Biological & Pharmaceutical Bulletin 33(11): 1847–1853.CrossRef
27.
Gu, Y., X.X. Sun, J.M. Ye, L. He, S.S. Yan, H.H. Zhang, L.H. Hu, J.Y. Yuan, and Q. Yu. 2012. Arctigenin alleviates ER stress via activating AMPK. Acta Pharmacologica Sinica 33(7): 941–952.PubMedCentralPubMedCrossRef
28.
Shen, S., J. Zhuang, Y. Chen, M. Lei, J. Chen, X. Shen, and L. Hu. 2013. Synthesis and biological evaluation of arctigenin ester and ether derivatives as activators of AMPK. Bioorganic & Medicinal Chemistry 21(13): 3882–3893.CrossRef
29.
Yin, H., X.B. Jin, Q. Gong, H. Yang, L.Y. Hu, F.L. Gong, and J.Y. Zhu. 2008. Fructose-1,6-diphosphate attenuates acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 8(13–14): 1842–1847.PubMedCrossRef
30.
MacCallum, N.S., and T.W. Evans. 2005. Epidemiology of acute lung injury. Current Opinion in Critical Care 11(1): 43–49.PubMedCrossRef
31.
Matthay, M.A., G.A. Zimmerman, C. Esmon, J. Bhattacharya, B. Coller, C.M. Doerschuk, J. Floros, M.A. Gimbrone Jr., E. Hoffman, R.D. Hubmayr, M. Leppert, S. Matalon, R. Munford, P. Parsons, A.S. Slutsky, K.J. Tracey, P. Ward, D.B. Gail, and A.L. Harabin. 2003. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. American Journal of Respiratory and Critical Care Medicine 167(7): 1027–1035.PubMedCrossRef
32.
Zhang, X., K. Song, H. Xiong, H. Li, X. Chu, and X. Deng. 2009. Protective effect of florfenicol on acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 9(13–14): 1525–1529.PubMedCrossRef
33.
Cepkova, M., and M.A. Matthay. 2006. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. Journal of Intensive Care Medicine 21(3): 119–143.PubMedCentralPubMedCrossRef
34.
Klebanoff, S.J. 2005. Myeloperoxidase: friend and foe. Journal of Leukocyte Biology 77(5): 598–625.PubMedCrossRef
35.
Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202(2): 145–156.PubMedCrossRef
36.
Ganter, M.T., J. Roux, B. Miyazawa, M. Howard, J.A. Frank, G. Su, D. Sheppard, S.M. Violette, P.H. Weinreb, G.S. Horan, M.A. Matthay, and J.F. Pittet. 2008. Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circulation Research 102(7): 804–812.PubMedCentralPubMedCrossRef
37.
Minamino, T., and I. Komuro. 2006. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. The Journal of Clinical Investigation 116(9): 2316–2319.PubMedCentralPubMedCrossRef
38.
Zanotti, S., A. Kumar, and A. Kumar. 2002. Cytokine modulation in sepsis and septic shock. Expert Opinion on Investigational Drugs 11(8): 1061–1075.PubMedCrossRef
39.
Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Critical Care Medicine 29(7 Suppl): S121–125.PubMedCrossRef
40.
Jean-Baptiste, E. 2007. Cellular mechanisms in sepsis. Journal of Intensive Care Medicine 22(2): 63–72.PubMedCrossRef
41.
Sag, D., D. Carling, R.D. Stout, and J. Suttles. 2008. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. Journal of Immunology (Baltimore, Md. : 1950) 181(12): 8633–8641.CrossRef
Metadata
Title
Arctigenin Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rats
Authors
Xianbao Shi
Hongzhi Sun
Dun Zhou
Huanjiu Xi
Lina Shan
Publication date
01-04-2015
Publisher
Springer US
Published in
Inflammation / Issue 2/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9969-z

Other articles of this Issue 2/2015

Inflammation 2/2015 Go to the issue

OriginalPaper

Exogenous IL-2 Controls the Balance in Th1, Th17, and Treg Cell Distribution in Patients with Progressive Rheumatoid Arthritis Treated with TNF-Alpha Inhibitors

OriginalPaper

Inhibition of Peripheral Nociceptors by Aminoglycosides Produces Analgesia in Inflammatory Pain Models in the Rat

OriginalPaper

Vitamin D Improves Cognitive Function and Modulates Th17/Treg Cell Balance After Hepatectomy in Mice

OriginalPaper

Chloroquine Differentially Modulates Inflammatory Cytokine Expression in RAW 264.7 Cells in Response to Inactivated Staphylococcus aureus

OriginalPaper

Platelet Factor 4 Protects Kidney Allograft in a Rat Kidney Transplantation Model

OriginalPaper

Incorporation of Eicosatrienoic Acid Exerts Mild Anti-inflammatory Properties in Murine RAW264.7 Cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits